CVRx (CVRX) Stock Forecast & Price Target

CVRx Inc. demonstrates a positive growth trajectory, as evidenced by the increase in active implanting centers, which rose to 240, reflecting a sequential increase of 13 centers. The company's revenue-generating potential remains robust, derived primarily from its proprietary Barostim platform, which addresses critical needs in cardiovascular healthcare. Although total operating expenses increased approximately 8% year-over-year to $25.8 million, the strategic focus on expanding its market presence indicates a commitment to long-term growth and viability in the medical device sector.

CVRx has revised its FY25 revenue guidance downward, now projecting a range of $55.0 to $57.0 million, indicating a growth of only 7-11% year-over-year, which raises concerns about the company's revenue scalability. Furthermore, the company's gross margin remained flat at approximately 84% in 2Q25, suggesting a lack of significant operational efficiency improvements. Additionally, the downward adjustment of the 2026 revenue estimate to $67.6 million from $74.1 million reflects a tempered outlook for growth in the U.S. market, further underscoring potential challenges in achieving robust financial performance.